Oric Pharmaceuticals, Inc.
ORICNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ORIC. That does not mean none is planned.
Get an email about ORIC's next catalysts
Track Oric Pharmaceuticals (ORIC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ORIC Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.41 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Rinzimetostat
Metastatic Castration Resistant Prostate Cancer
ORIC-114
Solid Tumors
Chemotherapy drug
Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rinzimetostat | Phase 3 | Metastatic Castration Resistant Prostate Cancer | - | - |
ORIC-114 | Phase 2 | Solid Tumors | - | - |
Chemotherapy drug | Phase 2 | Solid Tumors | - | - |
Frequently asked questions
What is in Oric Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Oric Pharmaceuticals, Inc.'s (ORIC) pipeline across Phase 3, Phase 2. Its lead program is Rinzimetostat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oric Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Oric Pharmaceuticals, Inc. (ORIC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ORIC biotech catalysts?→
Add ORIC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oric Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.